TLT — Theralase Technologies Cashflow Statement
0.000.00%
Last trade - 00:00- CA$48.20m
- CA$48.40m
- CA$1.03m
Annual cashflow statement for Theralase Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.6 | -4.41 | -5.24 | -4.57 | -4.26 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.93 | 0.342 | 0.241 | 0.648 | 0.555 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.05 | -0.238 | -0.452 | -0.436 | 0.103 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.45 | -4.03 | -5.13 | -4.07 | -3.33 |
| Capital Expenditures | -0.165 | -0.101 | -0.07 | -0.037 | -0.02 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.165 | -0.101 | -0.07 | -0.037 | -0.02 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.058 | -0.057 | 3.02 | 2.65 | 3.57 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.67 | -4.19 | -2.18 | -1.46 | 0.225 |